Dexamethasone Inhibits TGF-!1–Induced Cell Migration by Regulating the ERK and AKT Pathways in Human Colon Cancer Cells Via CYR61
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose One of the features in cancer development is the migration of cancer cells to form metastatic lesions. CYR61 protein promotes migration and the epithelial-mesenchymal transition in several cancer cell types. Evidence suggests that CYR61 and dexamethasone are relevant to colorectal cancer. However, relationships between them and colorectal cancer are still unclear. Understanding the molecular mechanism of colorectal cancer progression related with CYR61 and dexamethasone, which is widely used for combination chemotherapy, is necessary for improved therapy. Materials and Methods We used colorectal cancer cells, HCT116, co-treated with transforming growth factor !1 (TGF-!1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay. Alternatively, both migratory pathways, expression of AKT and ERK, and the target factor CYR61 was also tested by co-treatment with TGF-!1 and dexamethasone. Results We report that dexamethasone significantly inhibited TGF-!1–induced cell migration, without affecting cell proliferation. Importantly, we observed that TGF-!1 promoted the epithelial- mesenchymal transition process and that dexamethasone co-treatment abolished this effect. ERK and AKT signaling pathways were found to mediate TGF-!1–induced migration, which was inhibited by dexamethasone. In addition, TGF-!1 treatment induced CYR61 expression whereas dexamethasone reduced it. These observations were compatible with the modulation of migration observed following treatment of HCT116 cells with human recombinant CYR61 and anti-CYR61 antibody. Our results also indicated that TGF-!1 enhanced collagen I and reduced matrix metalloproteinase 1 expression, which was reversed by dexamethasone treatment. Conclusion These findings suggested that dexamethasone inhibits AKT and ERK phosphorylation, leading to decreased CYR61 expression, which in turn blocks TGF-!1–induced migration.
Abstract
Purpose One of the features in cancer development is the migration of cancer cells to form metastatic lesions. CYR61 protein promotes migration and the epithelial-mesenchymal transition in several cancer cell types. Evidence suggests that CYR61 and dexamethasone are relevant to colorectal cancer. However, relationships between them and colorectal cancer are still unclear. Understanding the molecular mechanism of colorectal cancer progression related with CYR61 and dexamethasone, which is widely used for combination chemotherapy, is necessary for improved therapy. Materials and Methods We used colorectal cancer cells, HCT116, co-treated with transforming growth factor !1 (TGF-!1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay. Alternatively, both migratory pathways, expression of AKT and ERK, and the target factor CYR61 was also tested by co-treatment with TGF-!1 and dexamethasone. Results We report that dexamethasone significantly inhibited TGF-!1–induced cell migration, without affecting cell proliferation. Importantly, we observed that TGF-!1 promoted the epithelial- mesenchymal transition process and that dexamethasone co-treatment abolished this effect. ERK and AKT signaling pathways were found to mediate TGF-!1–induced migration, which was inhibited by dexamethasone. In addition, TGF-!1 treatment induced CYR61 expression whereas dexamethasone reduced it. These observations were compatible with the modulation of migration observed following treatment of HCT116 cells with human recombinant CYR61 and anti-CYR61 antibody. Our results also indicated that TGF-!1 enhanced collagen I and reduced matrix metalloproteinase 1 expression, which was reversed by dexamethasone treatment. Conclusion These findings suggested that dexamethasone inhibits AKT and ERK phosphorylation, leading to decreased CYR61 expression, which in turn blocks TGF-!1–induced migration.
참고문헌 (25)
- Cunningham D, "Colorectal cancer", Lancet, 375, pp.1030~1047 (2010)
- Kalluri R, "The basics of epithelial-mesenchymal transition", J Clin Invest, 119, pp.1420~1428 (2009)
- Wells A, "E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas", Clin Exp Metastasis, 25, pp.621~628 (2008)
- Iwatsuki M, "Epithelial-mesenchymal transition in cancer development and its clinical significance", Cancer Sci, 101, pp.293~299 (2010)
- Steelman LS, "Roles of the Raf", MEK, PTEN, pp.Akt, mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging[DOI]
- Holbourn KP, "The CCN family of proteins : structure-function relationships", Trends Biochem Sci, 33, pp.461~473 (2008)
- Sun ZJ, "Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells", Br J Cancer, 99, pp.1656~1667 (2008)
- Terada N, "Cyr61 is a potential prognostic marker for prostate cancer", Asian J Androl, 14, pp.405~408 (2012)
- Jeong D, "Cyr61expression is associated with prognosis in patients with colorectal cancer", BMC Cancer, 14, pp.164~ (2014)
- Auphan N, "Immunosuppression by glucocorticoids : inhibition of NF-kappa B activity through induction of I kappa B synthesis", Science, 270, pp.286~290 (1995)
- Rinehart J, "Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model", Blood, 86, pp.4493~4499 (1995)
- Gundisch S, "Glucocorticoids augment survival and proliferation of tumor cells", Anticancer Res, 32, pp.4251~4261 (2012)
- Rinehart J, "Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer", Cancer Chemother Pharmacol, 71, pp.1375~1383 (2013)
- Singh PP, "Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy : follow-up analysis of a previous randomized controlled trial", Br J Anaesth, 113(Suppl 1), pp.68~73 (2014)
- 서가영, "The Protective Effect of Glycitin on UV-induced Skin Photoaging in Human Primary Dermal Fibroblast", Applied Biological Chemistry, 57(4), pp.463~468 (2014), 한국응용생명화학회
- Nicolas FJ, "Epithelial to mesenchymal transition in Madin-Darby canine kidney cells is accompanied by down-regulation of Smad3expression, leading to resistance to transforming growth factor-beta-induced growth arrest", J Biol Chem, 278, pp.3251~3256 (2003)
- Suman S, "Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells", Mol Carcinog, 53(Suppl 1), pp.151~160 (2014)
- Lau LF, "CCN1", CYR61 : the very model of a modern matricellular protein, 2011, pp.68, 3149~3163
- Haque I, "Cyr61", CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis, 2011, pp.10, 8~
- Chen J, "The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration", Mol Cell Biochem, 384, pp.269~277 (2013)
- Lee YJ, "Production of Cyr61 protein is modulated by extracellular acidification and PI3K", Akt signaling in prostate carcinoma PC-3 cells, 2013, pp.58, 169~176
- Shim SH, "Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line", Oncol Rep, 23, pp.1139~1143 (2010)
- Bernardi RJ, "Combination of 1alpha, 25-dihydroxyvitamin D(3)with dexamethasone enhances cell cycle arrest and apoptosis : role of nuclear receptor cross-talk and Erk", Akt signaling, 2001, pp.7, 4164~4173
- Jang YH, "Effects of dexamethasone on the TGF-!1-induced epithelialto-mesenchymal transition in human peritoneal mesothelial cells", Lab Invest, 93, pp.194~206 (2013)
- Sabile AA, "Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice", Biochim Biophys Acta, 1832, pp.1173~1182 (2013)